TLR5 activation by flagellin induces doxorubicin resistance via interleukin-6 (IL-6) expression in two multiple myeloma cells

Cellular Immunology

Volumn 289, Issue 1-2, 2014, Pages 27-35

  Cho, Hae Yun ^a,b   Lee, Soo Woong ^a,b,c  

^a Advanced Research Center for Multiple Myeloma   (South Korea)

^b Department of Microbiology and Immunology Busan 614 735 ^*  (South Korea)

^c Inje University   (South Korea)

Author keywords

Doxorubicin; Flagellin; IL 6; Multiple myeloma; TLR5

Indexed keywords

CASPASE; DOXORUBICIN; FLAGELLIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 6; TOLL LIKE RECEPTOR 5;

APOPTOSIS; ARTICLE; BACTERIAL INFECTION; CANCER RESISTANCE; CELL PROLIFERATION; CELL STIMULATION; CELL VIABILITY; CYTOKINE PRODUCTION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; INFECTION RISK; MULTIPLE MYELOMA; MYELOMA CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT INFECTION; SALMONELLA TYPHIMURIUM;

DOXORUBICIN; FLAGELLIN; IL-6; MULTIPLE MYELOMA; TLR5;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; B-LYMPHOCYTES; CASPASE INHIBITORS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FLAGELLIN; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-6; MULTIPLE MYELOMA; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 5;

EID: 84897557011     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2014.03.003     Document Type: Article

References (50)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M. Cancer statistics. CA Cancer J. Clin. 2009, 59:225-249.
2. Bataille R., Harousseau J.L. Multiple myeloma. N. Engl. J. Med. 1997, 336:1657-1664.
3. Raab M.S., Podar K., Breitkreutz I., Richardson P.G., Anderson K.C. Multiple myeloma. Lancet 2009, 25:324-339.
4. Kyle R.A., Rajkumar S.V. Multiple myeloma. N. Engl. J. Med. 2004, 351:1860-1873.
5. Khalafallah A., Maiwald M., Cox A., Burns D., Bates G., Hannan T., Seaton D., Fernandopulle B., Meagher D., Brain T. Effect of immunoglobulin therapy on the rate of infections in multiple myeloma patients undergoing autologous stem cell transplantation or treated with immunomodulatory agents. Mediterr. J. Hematol. Infect. Dis. 2010, 2:2010005.
6. Hideshima T., Anderson K.C. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat. Rev. Cancer 2002, 2:927-937.
7. Mitsiades C.S., Mitsiades N., Munshi N.C., Anderson K.C. Focus on multiple myeloma. Cancer Cell 2004, 6:439-444.
8. Podar K., Anderson K.C. The pathophysiological role of VEGF in hematological malignancies: therapeutic implications. Blood 2005, 105:1383-1395.
9. Landowski T.H., Olashaw N.E., Agrawal D., Dalton W.S. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B (RelB/p50) in myeloma. Oncogene 2003, 22:2417-2421.
10. Yasui H., Hideshima T., Richardson P.G., Anderson K.C. Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br. J. Haematol. 2005, 132:385-397.
11. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
12. Huang B., Zhao J., Li H., He K.L., Chen Y., Chen S.H., Mayer L., Unkeless J.C., Xiong H. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005, 65:5009-5014.
13. Bohnhorst J., Rasmussen T., Moen S.H., Flottum M., Knudsen L., Borset M., Espevik T., Sundan A. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006, 20:1138-1144.
14. Lee M.S., Kim Y.J. Signaling pathways downstream of pattern-recognition receptors and their cross talk. Annu. Rev. Biochem. 2007, 76:447-480.
15. Wolska A., Lech-Maranda E., Robak T. Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cell. Mol. Biol. Lett. 2009, 14:248-272.
16. Sebastiani G., Leveque G., Lariviere L., Laroche L., Skamene E., Gros P., Malo D. Cloning and characterization of the murine Toll-like receptor 5 (Tlr5) gene: sequence and mRNA expression studies in Salmonella-susceptible MOLF/Ei mice. Genomics 2000, 64:230-240.
17. Zarember K.A., Godowski P.J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 2002, 168:554-561.
18. Eaves-Pyles T.D., Wong H.R., Odoms K., Pyles R.B. Salmonella flagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the protein. J. Immunol. 2001, 167:7009-7016.
19. Dwyer J.M., Mackay I.R. Cellular immune response to flagellin in man. Int. Arch. Allergy Appl. Immunol. 1972, 43:434-445.
20. Rhee S.H., Im E., Pothoulakis C. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 2008, 135:518-528.
21. Sfondrini L., Rossini A., Besusso D., Merlo A., Tagliabue E., Menard S., Balsari A. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J. Immunol. 2006, 176:6624-6630.
22. Sehgal P.B., Wang L., Rayanade R., Pan H., Margulies L. Interleukin-6-type cytokines. Ann. NY Acad. Sci. 1995, 762:1-14.
23. Hirano T. The biology of interleukin-6. Chem. Immunol. 1992, 51:153-180.
24. Van Snick J. Interleukin-6: an overview. Annu. Rev. Immunol. 1990, 8:253-278.
25. Hitzler J.K., Martinez-Valdez H., Bergsagel D.B., Minden M.D., Messner H.A. Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease. Blood 1991, 15:1996-2004.
26. Voorhees P.M., Manges R.F., Sonneveld P., Jagannath S., Somlo G., Krishnan A., Lentzsch S., Frank R.C., Zweegman S., Wijermans P.W., Orlowski R.Z., Kranenburg B., Hall B., Casneuf T., Qin X., van de Velde H., Xie H., Thomas S.K. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 2013, 161(3):357-366.
27. Lichtenstein A., Tu Y., Fady C., Vescio R., Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell. Immunol. 1995, 162:248-255.
28. Hardin J., MacLeod S., Grigorieva I., Chang R., Barlogie B., Xiao H., Epstein J. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood 1994, 84:3063-3070.
29. Kovalovich K., Li W., DeAngelis R., Greenbaum L.E., Ciliberto G., Taub R. Interleukin-6 protects against Fas-mediated death by establishing a critical level of anti-apoptotic hepatic proteins FLIP, Bcl-2, and Bcl-xL. J. Biol. Chem. 2001, 276:26605-26613.
30. Raffo A.J., Perlman H., Chen M.W., Day M.L., Streitman J.S., Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res. 1995, 55:4438-4445.
31. Takeda K., Kaisho T., Yoshida N., Takeda J., Kishimoto T., Akira S. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: Generation and characterization of T cell-specific Stat3-deficient mice. J. Immunol. 1998, 161:4652-4660.
32. Tu Y., Renner S., Xu F., Fleishman A., Taylor J., Weisz J., Vescio R., Rettig M., Berenson J., Krajewski S., Reed J.C., Lichtenstein A. BCLX expression in multiple myeloma: possible indicator of hemoresistance. Cancer Res. 1998, 58:256-262.
33. Akira S., Takeda K. Toll-like receptor signaling. Nat. Rev. Immunol. 2004, 4:499-511.
34. Rhee S.H., Kim H., Moyer M.P., Pothoulakis C. Role of MyD88 in phosphatidylinositol 3-kinase activation by flagellin/toll-like receptor 5 engagement in colonic epithelial cells. J. Biol. Chem. 2006, 281:18560-18568.
35. Hutchison C.A., Batuman V., Behrens J., Bridoux F., Sirac C., Dispenzieri A., Herrera G.A., Lachmann H., Sanders P.W., International Kidney and Monoclonal Gammopathy Research Group The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat. Rev. Nephrol. 2011, 8:43-51.
36. Hakem R., Hakem A., Duncan G.S., Henderson J.T., Woo M., Soengas M.S., Elia A., de la Pompa J.L., Kagi D., Khoo W., Potter J., Yoshida R., Kaufman S.A., Lowe S.W., Penninger J.M., Mak T.W. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 1998, 94:339-352.
37. De Raeve H.R., Vanderkerken K. The role of the bone marrow microenvironment in multiple myeloma. Histol. Histopathol. 2005, 20:1227-1250.
38. Asosingh K., De Raeve H., de Ridder M., Storme G.A., Willems A., Van Riet I., Van Camp B., Vanderkerken K. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica 2005, 90:810-817.
39. Hu Y., Kirito K., Yoshida K., Mitsumori T., Nakajima K., Nozaki Y., Hamanaka S., Nagashima T., Kunitama M., Sakoe K., Komatsu N. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol. Cancer Ther. 2009, 8:2329-2338.
40. Jego G., Bataille R., Geffroy-Luseau A., Descamps G., Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006, 20:1130-1137.
41. Cai Z., Sanchez A., Shi Z., Zhang T., Liu M., Zhang D. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res. 2011, 71:2466-2475.
42. Gewirtz A.T., Simon P.O., Schmitt C.K., Taylor L.J., Hagedorn C.H., O'Brien A.D., Neish A.S., Madara J.L. Salmonella typhimurium translocates flagellin across intestinal epithelia inducing a proinflammatory response. J. Clin. Invest. 2001, 107:99-109.
43. Davies G., Wells A.U., Doffman S., Watanabe S., Wilson R. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur. Respir. J. 2006, 28:974-979.
44. Kishimoto T., Taga T., Yamasaki K., Matsuda T., Tang B., Muraguchi A., Horii Y., Suematsu S., Hirata Y., Yawata H. Normal and abnormal regulation of human B cell differentiation by a new cytokine, BSF2/IL-6. Adv. Exp. Med. 1989, 254:135-143.
45. Romano M., Sironi M., Toniatti C., Polentarutti N., Fruscella P., Ghezzi P., Faggioni R., Luini W., van Hinsbergh V., Sozzani S., Bussolino F., Poli V., Ciliberto G., Mantovani A. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997, 6:315-325.
46. Legrand O., Simonin G., Beauchamp-Nicoud A., Zittoun R., Marie J.P. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 1999, 94:1046-1056.
47. Magnarin M., Morelli M., Rosati A., Bartoli F., Candussio L., Giraldi T., Decorti G. Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells. Eur. J. Pharmacol. 2004, 483:19-28.
48. Garay R.P., Viens P., Bauer J., Normier G., Bardou M., Jeannin J.F., Chiavaroli C. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur. J. Pharmacol. 2007, 563:1-17.
49. Galluzzi L., Vacchelli E., Eggermont A., Fridman W.H., Galon J., Sautès-Fridman C., Tartour E., Zitvogel L., Kroemer G. Trial watch: experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012, 1:699-716.
50. Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy 2009, 1:949-964.